➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
Harvard Business School
McKesson
Dow

Last Updated: April 21, 2021

DrugPatentWatch Database Preview

Divalproex sodium - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for divalproex sodium and what is the scope of freedom to operate?

Divalproex sodium is the generic ingredient in four branded drugs marketed by Abbvie, Ajanta Pharma Ltd, Dr Reddys Labs Ltd, Mylan, Teva Pharms Usa, Zydus Pharms Usa Inc, Abbott, Actavis Labs Fl Inc, Anchen Pharms, Apotex, Aurobindo Pharma Ltd, Celltrion, Invatech, Lupin, Orchid Hlthcare, Prinston Inc, Sun Pharm Inds, Teva, Unichem Labs Ltd, Upsher Smith Labs, Amneal Pharms, Cosette, Impax Labs, Lupin Ltd, Reddys, and Wockhardt, and is included in thirty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for divalproex sodium. Forty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for divalproex sodium

See drug prices for divalproex sodium

Drug Sales Revenue Trends for divalproex sodium

See drug sales revenues for divalproex sodium

Recent Clinical Trials for divalproex sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidad Autonoma de San Luis PotosíPhase 3
Puma Biotechnology, Inc.Phase 1/Phase 2
Virginia Commonwealth UniversityPhase 1/Phase 2

See all divalproex sodium clinical trials

Generic filers with tentative approvals for DIVALPROEX SODIUM
Applicant Application No. Strength Dosage Form
  Start Trial  Start TrialEQ 500MG VALPROIC ACIDTABLET, DELAYED RELEASE;ORAL
  Start Trial  Start TrialEQ 250MG VALPROIC ACIDTABLET, DELAYED RELEASE;ORAL
  Start Trial  Start TrialEQ 125MG VALPROIC ACIDTABLET, DELAYED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DIVALPROEX SODIUM
Tradename Dosage Ingredient NDA Submissiondate
DEPAKOTE ER TABLET, EXTENDED RELEASE;ORAL divalproex sodium 021168 2005-02-08
DEPAKOTE ER TABLET, EXTENDED RELEASE;ORAL divalproex sodium 021168 2004-05-03
DEPAKOTE TABLET, DELAYED RELEASE;ORAL divalproex sodium 018723

US Patents and Regulatory Information for divalproex sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan DIVALPROEX SODIUM divalproex sodium TABLET, DELAYED RELEASE;ORAL 090062-001 Mar 17, 2009 DISCN No No   Start Trial   Start Trial   Start Trial
Wockhardt DIVALPROEX SODIUM divalproex sodium TABLET, EXTENDED RELEASE;ORAL 078705-001 Aug 4, 2009 AB RX No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd DIVALPROEX SODIUM divalproex sodium TABLET, EXTENDED RELEASE;ORAL 202419-001 Jun 2, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for divalproex sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Express Scripts
Colorcon
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.